From protocol amendments to participant recruitment and retention, the impact of COVID-19 could be enormous. What can you do to minimize the disruption to your ongoing, or upcoming, clinical trial? Our panel of experts from NYU Langone Medical Center and WCG discuss ways to reduce the impact of this pandemic on your studies to keep them on track.
Request a Genetics in Clinical Trials training session
What You'll LearnMost Recent Flipbooks
Clinical Research Trends & Insights for 2020
16 industry experts share shifts and trends that will inform clinical research in 2020 and beyond.
Advances in Oncology Extend Lives, but Lead to New Safety Considerations for Sponsors and Investigators
From cardiovascular adverse events to complex dosing regimens, oncology trials present unique safety-related considerations.
The Most Important Voice Is Missing: The Case For Including Patient Insights In Protocol Design
Something Has to Give: The Current Unsustainable Approach to Safety Reporting Puts Trials and Patients at Risk
Something Has to Give: The Current Unsustainable Approach to Safety Reporting Puts Trials and Patients at Risk
Part 10: Unique Challenges and Opportunities for Emerging Biopharma Companies with Focused Pipelines
Part 6: Going Remote During COVID-19: Considerations When Moving Studies Out of the Clinic Setting
Part 4: Planning for Recovery: How Research Sponsors and Research Sites are Thinking Ahead to Restart Research
Part 3: Evaluating Study Status and Leveraging Data Monitoring Committees to Make Study Decisions
Part 2: The Necessary Changes that Sites, Institutions and Research Participants are Considering During the COVID-19 Crisis
The Power to Pivot: Decoding CNS Trials with Data Analytics
In this interview, Jesse Kooker, MPH, VP of Clinical Data Sciences at WCG's MedAvante-ProPhase, looks at the clinical development industry through the lens of data analytics.
Site-specific, Patient-centered and Whip-smart: Enrollment Assistants Adapt to a Shifting Landscape
